NICE recommends Jardiance (empagliflozin) for T2D-Boehringer/Lilly

NICE has issued its Final Appraisal Determination recommending Jardiance (empagliflozin), from Boehringer/Eli Lilly, for use within the UK National Health Service in the treatment of Type 2 Diabetes as follows: empagliflozin in a dual therapy regimen in combination with metformin is recommended as an option for treating type 2 diabetes, only if a sulfonylurea is contraindicated or not tolerated, or the person is at significant risk of hypoglycaemia or its consequences. Empagliflozin in a triple therapy regimen is recommended as an option for treating type 2 diabetes in combination with metformin and a sulfonylurea or metformin and a thiazolidinedione. Empagliflozin in combination with insulin with or without other antidiabetic drugs is recommended as an option for treating type 2 diabetes. People currently receiving treatment initiated within the NHS with empagliflozin that is not recommended for them by NICE in this guidance should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.